Conclusions
We identify that the dose of thalidomide between 2.5 mg·kg-1·d-1 to
3.6mg·kg-1·d-1 is effective in 67.5% to 80.5% children with TDT, which
is the first available protocol in this indication. Dizziness, lethargy,
constipation, abdominal pain, vomiting and nausea are most commonly
seen, but most of the symptoms relieve spontaneously. Severe side
effects are uncommon. Moreover, HbF concentration of 47.298 g·L-1 at the
third month is recommended as the predictor for further major
responders.